On July 6, 2023, the first-ever intracranial flow disruption device developed by Shanghai Micro Medical Technology Co., Ltd. (MeshCoil®) successfully completed enrollment of all patients, in a nationwide multi-center registered clinical trial led by Professor Hongqi Zhang , the director of the Neurosurgery Department of Xuanwu Hospital of Capital Medical University. This trial, known as MCOINA-MeshCoil In China, marks a significant achievement.
Notably, MeshCoil® received approval from the National Medical Products Administration (NMPA) for innovative medical devices in the latter half of 2022, gaining access to the esteemed "green channel." This latest development represents another important milestone in medical innovation.
As a CRO company participating in this research, Links Medical Scientific (Shanghai) Co., Ltd.(LINKS) upholds the "LINKS" principles, efficiently facilitating collaboration between sponsors, researchers, and various centers, to drive the project's progress effectively. From providing medical support to executing the project, LINKS proactively responds to the needs of all stakeholders, assisting in making this product the first domestically developed intracranial flow disruption device for aneurysms to successfully complete nationwide multi-center clinical enrollment. This achievement marks a significant stride forward for domestically produced similar medical devices.
In the future, LINKS will continue to uphold its original mission, assisting enterprises in enhancing research and development efficiency, ensuring high-quality delivery of research projects, and accelerating the process of bringing products to market, ultimately bringing positive outcomes for patients.
LINKS CRO
As a CRO company providing clinical trial services. LINKS CRO focus on innovation, high-risk implantation(intervention) medical device, with one-stop clinical trial solutions for the whole process of medical device research and development.The headquarters of LINKS is based in Shanghai, with subsidiary branches in Beijing, Shanghai, Guangzhou, and Shenzhen, in addition to ten regional offices. The current workforce comprises almost 200 employees, with technical personnel making up over 85% and dispersed across almost 30 cities nationwide.
Key Services include CRO, SMO, CER, Audit, Post-market research, core laboratory registration both domestically and overseas, innovation declaration, Expert Consultancy, and overseas enterprise agency services.
Key Indications include Cardiovascular, Neurovascular, Peripheral Vascular, Surgery Robot, Oncology, Ophthalmology, Medical Cosmetology, and other fields such as orthopedics. There are almost 300 projects consultations and services by LINKS each year.
